Table 1: Showing baseline study characteristics, demographics and comorbidities among included studies. Data presented in experimental/control group pattern.

**Abbreviations:** HCQ: Hydroxychloroquine, AZ: Azithromycin, IgG: Immunoglobulin, HTN: Hypertension, HLD: Hyperlipidemia, DM: Diabetes Mellitus, ESRD: End Stage Renal Disease, CKD: Chronic Kidney Disease, CPD: Chronic Pulmonary Disease, URTI: Upper Respiratory Tract Infections, LRTI: Lower Respiratory Tract Infections, SBP: systolic blood pressure, RR: Respiratory Rate, O2 Sats/Min: Oxygen Saturation Per Minutes, ACEi: Angiotensin Converting Enzyme Inhibitors, ARB: Angiotensin II Receptor Blockers

|  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| **Characteristics** | **Gautret 5** | **Borba 9** | **Magagnoli 10** | **Mahevas 11** | **Chen J 7** | **Huang 8** | **Lu 13** | **Tang 12** | **Chen Z 6** | **Rosenberg 15** | **Carlucci 14** | **Geleris 16** | **Zhaowei 18** | **Mallat 17** |
| **Country** | France | Brazil | USA | France | China | China | China | China | China | USA | USA | USA | China | Abu Dhabi |
| **Design** | NR-RCT | RCT | Retrospective | Retrospective | Pilot RCT | RCT | RCT | MC OL RCT | RCT | Retrospective | Retrospective | Observational  | RCT | Observational |
| **Total Sample n** | 36 | 440 | 368 | 181 | 30 | 22 | 30 |   |   | 1438 | 932 | 1446 | 62 | 34 |
| **HCQ/Placebo** | 26/16 |   | 113/158 | 84/97 |   | 10./12 |   | 70/80 |   | 735/221 | 411/521 | 811/ 274 | 31/31 | 23/11 |
| **Mean age**  | 45.1±22.0 | 51.1 | 68 | 60 | 48.6 | 44 |   | 46 |   | 61.4 | 63.19 + 15.1 |   |   | 37 |
| **Males (%) n=** | 15% | 61 |   | 71% | 21 (70%) | 12 (59%) |   | 82 (54%) |   | 67% |   |   |   | 25% |
| **Age HCQ/Control** |   |   |   |   | 50.5 ± 3.8/46.7 ± 3.6 | 41.5/53 |   | 48/44 |   |   |   |   |   | 33/41 |
| **Race (n)** |   |   |   |   |   |   |   |   |   |   |   |   |   |   |
| **Caucasions** |   | 17 | 39/43 |   |   |   |   |   |   | 167/61 |   |   |   |   |
| **White** |   |   |   |   |   |   |   |   |   | 167/ 61 | 189/244 | 97/36 |   |   |
| **Black** |   | 6 | 67/103 |   |   |   |   |   |   | 199/ 50 | 68/81 | 120/40 |   |   |
| **Multiracial/unknown** |   |   |   |   |   |   |   |   |   |   | 27/24 |   |   |   |
| **Asian** |  |   |   |   |   |   |   |   |   |   | 30/30 |   |   |   |
| **Hispanic** |   |   |   |   |   |   |   |   |   | 199/ 67 |   | 530/172 |   |   |
| **Other** |   | 58 | 12/7 |   |   |   |   |   |   | 128/ 35 | 97/142 | 64/26 |   |   |
| **HTN**  |   | 25/55 |   | 38/56 | 3/5 | 3/1 |   | 3/6 |   | 426/ 121 | 154/208 | 398/146 |   | 0/5 |
| **Heart Failure** |   |   | 15/35 | 5-Jan |   |   |   |   |   | 46/ 11 | 26/22 |   |   | 0/1 |
| **HLD**  |   |   | 20/23 |   |   |   |   |   |   |   | 99/148 |   |   |   |
| **DM** |   | 14/55 | 77/110 | 11/4 | 1/1 | 1/1 |   | 9/12 |   | 269/ 64 | 105/130 | 301/94 |   | 0/2 |
| **ESRD or CKD** |   | 3/1 | 24/43 | 8/1 |   |   |   |   |   | 88/ 31 | 47/44 | 133/61 |   | 0/1 |
| **Asthma or CPD** |   | 4/54 | 10/9 | 15/5 |   |   |   |   |   | 129/ 24 |   | 146/49 |   | 2/1 |
| **Smoking** |   | 15 | 13/21 |   |   | 2/0 |   |   |   |   |   | 89/32 |   |   |
| **current**  |   |   |   |   |   |   |   |   |   | 25/ 6 | 29/24 |   |   |   |
| **former** |   |   |   |   |   |   |   |   |   | 100/ 27 | 76/115 |   |   |   |
| **never** |   |   |   |   |   |   |   |   |   | 422/ 130 | 306/282 |   |   |   |
| **BMI>30** |   |   |   | 20/23 |   |   |   |   |   | 264/ 39 |   | 268/99 |   |   |
| **URTI (n)** | 12 |   |   |   |   |   |   |   |   |   |   |   |   |   |
| **LRTI (n)** | 6 |   |   |   |   |   |   |   |   |   |   |   |   |   |
| **Asymptomatic** | 2 |   |   |   |   |   |   |   |   |   |   |   |   |   |
| **Temperature (C)** |   |   | 36.6-36.6 |   |   |   |   |   |   |   |   |   |   | 37 |
| **SBP** |  - | 94 | 132-129 | 124/130 |   |   |   |   |   |   | 134.83 + 20.84/132.41 + 21.87 | 125/126 |   |   |
| **RR** |  - | 26 | 20-18 | 27-36 |   |   |   |   |   |   | 20/20 | 20/19.5 |   | 19 |
| **02 sats/min** |  - |   | 95-96 | 92-99 |   |   |   |   |   |   | 94/94 | 94/94.5 |   |   |
| **SBP <90** |  - |   |   |   |   |   |   |   |   | 76/24 |   |   |   |   |
| **ACEi** |  - |   | 17/19 |   |   |   |   |   |   |   |   |   |   |   |
| **ARB** |  - |   | 8./16 |   |   |   |   |   |   |   |   |   |   |   |
| **HCQ Dose (mg)** | 600 OD | 600 OD |   | 600 OD | 400 OD | 500 OD | 400 OD |   |   |   | 400 loading doses>200 BID with Zinc 220 mg | 600 OD x 1 >400 OD for 4 days | 400 mg QD for 5 days | 400 BID (day 1) then 400 QD for 10 days |
| **Chloroquine Dose (mg)** |  - | 600-450 |   |   |   |   |   |   |   |   |   |   |   |   |
| **Azithromycin Dose (mg)** |  - |   |   |   |   |   |   |   |   |   | 500 QD | 500 QD x 1 >250 OD for 4 days |   |   |
| **Control Arm** |  Not available |  Usual care |    Standard treatment |    Standard treatment |  Standard treatment |      Standard treatment |    Standard treatment |      Standard treatment |      Standard treatment |  HCQ, HCQ+AZ, AZ, None | Azithro/HCQ |    Standard treatment |    Standard treatment O2, AV, IgG, steroids |    Standard treatment |
| **Duration of treatment** | 10 |   | 7 |   |   |   |   |   |   |   | 5 | 5 |   |   |
| **Primary Outcome** | virologic clearance | QT prolongation | Ventilation requirement |   | negative conversion rate | Virologic clearance by negative PCR | Rate of virologic cure |   |   | in hospital mortality |   | composite of intubation or death | Time to clinical recovery, CT Changes | RT-PCR negatuve on day 14 |
| **Secondary Outcome** | Side effects | mortality | mortality |   |   |   |   |   |   | Cardiac arrest and abnormal EKG findings  |   |   |   |   |

[5] Gautret P, Lagier JC, Parola P, Hoang VT, Meddeb L, Mailhe M, et al. Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial. Int J Antimicrob Agents 2020;105949.

[6] Chen Z, Hu J, Zhang Z, Jiang S, Han S, Yan D, et al. Efficacy of hydroxychloroquine in patients with COVID-19: results of a randomized clinical trial. medRxiv 2020;2020.03.22.20040758.

[7] CHEN Jun LD, LIU Li,LIU Ping,XU Qingnian,XIA Lu,LING Yun,HUANG Dan,SONG Shuli,ZHANG Dandan,QIAN Zhiping,LI Tao,SHEN Yinzhong,LU Hongzhou. A pilot study of hydroxychloroquine in treatment of patients with moderate COVID-19. J Zhejiang Univ (Med Sci) 2020;49:215-9.

[8] Huang M, Tang T, Pang P, Li M, Ma R, Lu J, et al. Treating COVID-19 with Chloroquine. J Mol Cell Biol 2020;12:322-5.

[9] Borba MGS, Val FdA, Sampaio VS, Alexandre MAA, amp, amp, et al. Chloroquine diphosphate in two different dosages as adjunctive therapy of hospitalized patients with severe respiratory syndrome in the context of coronavirus (SARS-CoV-2) infection: Preliminary safety results of a randomized, double-blinded, phase IIb clinical trial (CloroCovid-19 Study). medRxiv 2020;2020.04.07.20056424.

[10] Magagnoli J, Narendran S, Pereira F, Cummings T, Hardin JW, Sutton SS, et al. Outcomes of hydroxychloroquine usage in United States veterans hospitalized with Covid-19. medRxiv 2020;2020.04.16.20065920.

[11] Mahevas M, Tran V-T, Roumier M, Chabrol A, Paule R, Guillaud C, et al. No evidence of clinical efficacy of hydroxychloroquine in patients hospitalized for COVID-19 infection with oxygen requirement: results of a study using routinely collected data to emulate a target trial. medRxiv 2020;2020.04.10.20060699.

[12] Tang W, Cao Z, Han M, Wang Z, Chen J, Sun W, et al. Hydroxychloroquine in patients mainly with mild to moderate COVID-19: an open-label, randomized, controlled trial. medRxiv 2020;2020.04.10.20060558.

[13] Lu CC, Chen MY, Chang YL. Potential therapeutic agents against COVID-19: What we know so far. J Chin Med Assoc 2020.

[14] Carlucci P, Ahuja T, Petrilli CM, Rajagopalan H, Jones S, Rahimian J. Hydroxychloroquine and azithromycin plus zinc vs hydroxychloroquine and azithromycin alone: outcomes in hospitalized COVID-19 patients. medRxiv 2020;2020.05.02.20080036.

[15] Rosenberg ES, Dufort EM, Udo T, Wilberschied LA, Kumar J, Tesoriero J, et al. Association of Treatment With Hydroxychloroquine or Azithromycin With In-Hospital Mortality in Patients With COVID-19 in New York State. JAMA 2020.

[16] Geleris J, Sun Y, Platt J, Zucker J, Baldwin M, Hripcsak G, et al. Observational Study of Hydroxychloroquine in Hospitalized Patients with Covid-19. New England Journal of Medicine 2020.

[17] Mallat J, Hamed F, Balkis M, Mohamed MA, Mooty M, Malik A, et al.Hydroxychloroquine is associated with slower viral clearance in
clinical COVID-19 patients with mild to moderate disease: A
retrospective study [Internet]. Infectious Diseases (except HIV/AIDS);
2020 May [cited 2020 May 7]
[18] Zhaowei C, Jijia H, Zongwei Z, Shan J, Shoumeng H, Dandan Y,
Ruhong Z, Ben H, Zhan Z.
Efficacy of hydroxychloroquine in patients with COVID-19: results of a
randomized clinical trial. medRxiv 2020.03.22.20040758;